Quanta’s KRAS Drugs Tackle Next-Gen Cancer Treatment Resistance

RADNOR, Pa. – March 05, 2026 – In the relentless battle against cancer, drug resistance remains the most formidable adversary, often thwarting even the most advanced therapies. Quanta Therapeutics today announced a significant potential breakthrough in this fight, presenting preclinical data that shows its direct multi-KRAS inhibitors can overcome resistance to a newer class of drugs known as pan-RAS tri-complex inhibitors (TCIs).

The findings, unveiled at the AACR Special Conference on RAS Oncogenesis and Therapeutics in Los Angeles, suggest a vital new strategy for treating patients with KRAS-mutated cancers, particularly those whose tumors have learned to evade sophisticated treatments like daraxonrasib. This development offers a potential second line of attack, promising to extend the runway for patients who have exhausted other options.

The Challenge of an Evolving Target

The RAS family of genes, and particularly the KRAS variant, are among the most frequently mutated oncogenes in human cancers, driving tumor growth in a vast number of pancreatic, colorectal, and lung cancers. For decades, RAS was considered an “undruggable” target due to its smooth protein structure, which lacked obvious pockets for drugs to bind.

That paradigm shifted dramatically with the arrival of KRAS G12C inhibitors like Amgen's sotorasib and Bristol Myers Squibb's adagrasib, which proved the target could be hit. However, these drugs are specific to a single mutation, KRAS G12C. The next evolution came in the form of pan-RAS inhibitors, such as Revolution Medicines' daraxonrasib. These innovative tri-complex inhibitors were designed to target the active “ON” state of RAS, hitting multiple mutation types and offering a broader therapeutic window.

Daraxonrasib has shown significant promise in late-stage trials, particularly in notoriously difficult-to-treat pancreatic cancer, earning it a Breakthrough Therapy Designation from the FDA. Yet, like all targeted therapies, it faces the inevitable emergence of resistance. Cancers are masters of adaptation, and studies have shown that tumors treated with TCIs can develop new mutations or activate alternative signaling pathways to bypass the drug's effects, limiting the durability of patient responses.

Quanta’s Counter-Maneuver Against Resistance

Quanta Therapeutics' new data directly confronts this next-generation resistance problem. The company’s research focused on its two lead candidates: QTX3034, which is G12D-preferring, and QTX3544, which is G12V-preferring. These mutations are highly prevalent in aggressive cancers like pancreatic and colorectal tumors.

In preclinical studies using KRAS-mutated colorectal cancer cells, Quanta demonstrated that these direct multi-KRAS inhibitors retained potent activity even after the cells had acquired resistance to the pan-RAS inhibitor daraxonrasib. The research not only confirmed previously known resistance pathways but also identified novel mutations specific to TCI therapies, underscoring the complexity of RAS reactivation.

“While pan-RAS tri-complex inhibitors have demonstrated a broad potential to treat various KRAS-driven cancers, acquired resistance mechanisms have limited the depth and durability of clinical benefit, particularly with heterogeneous tumors such as colorectal cancer,” said Cameron Pitt, PhD, Co-Founder and Chief Operating Officer of Quanta Therapeutics, in a statement. “Our data confirm previously reported resistance pathways, identify novel mutations uniquely associated with this class of therapies and demonstrate the ability of our drug candidates to overcome key tri-complex inhibitor resistance mechanisms.”

The findings suggest a powerful sequencing strategy in the clinic: for patients who initially respond to a pan-RAS inhibitor but eventually relapse due to acquired resistance, a direct KRAS inhibitor from Quanta could provide a subsequent, effective line of therapy.

Navigating a Crowded and Competitive Field

Quanta's announcement lands in the middle of a fiercely competitive and rapidly advancing KRAS inhibitor landscape. The field is no longer just about the first-generation G12C inhibitors. A wave of companies is now racing to develop drugs for other mutations like G12D and G12V, as well as new pan-KRAS agents.

Revolution Medicines is pushing its pan-RAS TCI daraxonrasib toward the market, while Mirati Therapeutics (now part of Bristol Myers Squibb) is advancing its own G12D inhibitor, MRTX1133. Other players like Verastem Oncology and Incyte are also in clinical trials with their own G12D-targeting molecules. The very same day as Quanta's announcement, Kestrel Therapeutics revealed it had received IND clearance for its own pan-KRAS inhibitor, highlighting the intense pace of innovation.

Within this crowded space, Quanta is carving out a distinct niche. Its strategy is not just about targeting a specific mutation but about providing a solution to a problem created by the field's most advanced players. By positioning its drugs as a way to overcome TCI resistance, Quanta differentiates itself from competitors and establishes a clear potential role in the future treatment paradigm for RAS-driven cancers.

“As the field continues to evolve, patients with KRAS-mutated cancers will require multiple distinct drug mechanisms to combat the propensity for RAS reactivation,” Pitt added. “Studies like this deepen our understanding of resistance biology and can inform strategies to optimize patient outcomes.”

From Preclinical Promise to Patient Hope

While the data presented at AACR are preclinical, Quanta Therapeutics is already translating its science into clinical reality. The company, which has raised over $142 million from prominent investors including AbbVie Ventures and Longitude Capital, is actively enrolling patients in Phase 1 trials for both QTX3034 and QTX3544.

Early results from these trials are encouraging. QTX3034, both as a monotherapy and in combination with the EGFR inhibitor cetuximab, has already demonstrated meaningful anti-tumor activity. The company has reported confirmed complete responses in heavily pre-treated endometrial cancer patients and partial responses in refractory colorectal and pancreatic cancer patients.

This early clinical validation lends significant weight to the new preclinical resistance data. It suggests that the company's unique approach—using a proprietary Second Harmonic Generation (SHG) optical technology platform to identify its drug candidates—is yielding molecules with real-world potential. For patients with KRAS-mutant cancers, who often face a grim prognosis after initial therapies fail, this layered approach of developing drugs that can be sequenced to overcome resistance offers a crucial new dimension of hope, potentially turning a short-term response into a longer, more durable period of disease control.